T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-06-06Clinical Trial Update: CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia [NA]
A clinical trial evaluating a CD7-targeted CAR-T cell therapy for relapsed/refractory CD7-positive T-cell lymphoma and CD7-positive acute ly…
-
CLINICAL_TRIALS research · 2025-05-21Clinical Trial Update: A Registry for People With T-cell Lymphoma
A registry study at Memorial Sloan Kettering Cancer Center to enroll people with various T-cell and NK-cell lymphomas; the trial is currentl…
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma [Phase 2]
A multi-center, open-label Phase 2 trial evaluating the efficacy and safety of donor-derived CD7 CAR T cells in relapsed or refractory T-cel…
-
CLINICAL_TRIALS research · 2025-05-15Clinical Trial Update: A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas [Phase 1, Phase 2]
Clinical trial update for Tulmimetostat DZR123 (CPI-0209) in adults with advanced solid tumors and various lymphomas. The study is in Phase …
-
CLINICAL_TRIALS research · 2025-04-30Clinical Trial Update: Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies [Phase 1]
A Phase 1 clinical trial (NCT06699771) is evaluating the safety, tolerability, and preliminary efficacy of GCC2005. The trial focuses on pat…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS other · 2025-04-16Clinical Trial Update: A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma [Phase 1]
A Phase 1 dose-escalation study of CPI-818 in relapsed/refractory T-cell lymphoma is currently active but not recruiting. The trial is spons…
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors [Phase 1, Phase 2]
Ongoing Phase 1/Phase 2 trials are evaluating CAR-T cell therapy for relapsed or refractory malignant hematologic tumors, including aggressi…
-
CLINICAL_TRIALS research · 2025-04-03Clinical Trial Update: Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies [Phase 1]
Phase 1 clinical trial evaluating a CD5-targeted CAR-NK cell therapy for relapsed/refractory T-cell hematologic malignancies (T-ALL and T-ce…
-
CLINICAL_TRIALS research · 2025-03-20Clinical Trial Update: Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating the combination of pembrolizumab and brentuximab vedotin in relapsed/refractory T-cell lymphoma is curre…
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy
A completed clinical trial investigated the role of large extracellular vesicles as biomarkers in various lymphomas and lymphoproliferative …
-
CLINICAL_TRIALS trial_result · 2025-01-08Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) [Phase 1]
The COBALT-LYM Phase 1 trial evaluating CTX130 in relapsed or refractory T- or B-cell malignancies has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-12-12Clinical Trial Update: CAR-37 T Cells in Hematologic Malignancies [Phase 1]
Phase 1 trial update on CAR-37 T cells in hematologic malignancies shows the study has completed.
-
CLINICAL_TRIALS trial_result · 2024-12-06Clinical Trial Update: Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies [Phase 1]
Phase 1 clinical trial studying tagraxofusp in pediatric patients with CD123-expressing hematologic malignancies is currently recruiting, sp…
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia [Phase 1]
This is a Phase 1 clinical trial evaluating CD70-CAR-NK cell therapy for relapsed/refractory T-cell lymphoma and relapsed/refractory acute m…
-
CLINICAL_TRIALS trial_result · 2024-11-14Clinical Trial Update: Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma [Phase 1]
Phase I trial update for autologous CD7-CAR T cell therapy in high-risk acute T-cell leukemia/lymphoma; the study has completed.
-
CLINICAL_TRIALS trial_result · 2024-08-16Clinical Trial Update: Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) [Phase 1]
Phase 1 trial results evaluate palbociclib in combination with chemotherapy for pediatric patients with relapsed acute lymphoblastic leukemi…
-
CLINICAL_TRIALS trial_result · 2024-04-04Clinical Trial Update: Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas [Phase 1, Phase 2]
Phase 1/2 study evaluating the combination of carfilzomib, romidepsin, and lenalidomide in relapsed or refractory T-cell lymphomas; trial co…
-
CLINICAL_TRIALS trial_result · 2024-03-18Clinical Trial Update: HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma [Phase 2, Phase 3]
Phase 2/Phase 3 trial update for HuMax-CD4 in T cell lymphoma has completed recruitment.
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma [Phase 2]
Phase II study of Imtox-25 in adults with refractory/relapsed CD25-positive Adult T Cell Leukemia/Lymphoma has been terminated; results post…
-
CLINICAL_TRIALS trial_result · 2022-10-28Clinical Trial Update: Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma [Phase 1, Phase 2]
Clinical trial update reports safety and efficacy results for Tenalisib (RP6530) in combination with Romidepsin in relapsed/refractory T-cel…
-
CLINICAL_TRIALS trial_result · 2022-09-29Clinical Trial Update: Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma [Phase 2]
Phase 2 clinical trial updating efficacy and safety of chidamide with BEAM pretreatment for autologous transplantation in T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-07-25Clinical Trial Update: ChiCGB vs BEAM in High-risk or R/R Lymphomas [Phase 3]
Phase 3 clinical trial comparing ChiCGB to BEAM in high-risk or refractory/relapsed lymphomas is listed with phase 3 and unknown status.
-
CLINICAL_TRIALS trial_result · 2022-05-17Clinical Trial Update: Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment [Phase 1, Phase 2]
Clinical trial update on clofarabine in relapsed or refractory T-cell or NK-cell non-Hodgkin's lymphoma (Phase 1/2) completed with posted re…
-
CLINICAL_TRIALS trial_result · 2022-04-05Clinical Trial Update: Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL [Phase 1, Phase 2]
Phase 1/2a dose-escalation study in CLL/SLL and various NHL subtypes completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-09-28Clinical Trial Update: CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma [Phase 2]
Phase 2 clinical trial update for CD7 CAR T-cell therapy in refractory/relapsed CD7+ T cell lymphoma.